Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Acta Derm Venereol ; 103: adv6579, 2023 Aug 16.
Article in English | MEDLINE | ID: mdl-37584092

ABSTRACT

Artificial daylight photodynamic therapy is a near-painless treatment for actinic keratoses, which can be performed indoors using a controlled light dose. Daylight photodynamic therapy is approved only for treatment of grade I-II actinic keratoses. The aim of this study was to evaluate whether fractional laser pre-treatment improves the outcomes of daylight photodynamic therapy for actinic keratoses of all grades. In addition, the study compared the outcomes of artificial and natural daylight photodynamic therapy. This randomized single-blinded split-side comparative study included 60 patients with ≥ 2 actinic keratoses of the head. Fractional laser pre-treatment was assigned randomly for actinic keratoses on 1 side of the head and, subsequently, the entire treatment area was treated with artificial or natural daylight photodynamic therapy. Fractional laser-mediated daylight photodynamic therapy achieved significantly higher complete clearance (50.0% vs 30.3%, p = 0.04), partial clearance (78.6% vs 50.0%, p < 0.01) and lesion-specific clearance (86.2% vs 70.2%, p < 0.01) than daylight photodynamic therapy alone at the 6-month follow-up. No significant differences were found in the outcomes of artificial vs natural daylight photodynamic therapy or grade I lesions vs grade II-III lesions. Thus, fractional laser pre-treatment appears to significantly increase the efficacy of artificial and natural daylight photodynamic therapy, and to be suitable for treatment of actinic keratoses of all grades.


Subject(s)
Keratosis, Actinic , Laser Therapy , Photochemotherapy , Laser Therapy/methods , Photosensitizing Agents , Keratosis, Actinic/diagnosis , Keratosis, Actinic/therapy , Finland , Treatment Outcome , Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over
2.
BMC Health Serv Res ; 21(1): 166, 2021 Feb 22.
Article in English | MEDLINE | ID: mdl-33618714

ABSTRACT

BACKGROUND: Information about health care use and costs of cutaneous T-cell lymphoma (CTCL) patients is limited, particularly in a European setting. METHODS: In this population-wide study we set out to investigate prevalence, and trends in health care use in two CTCL subtypes, mycosis fungoides (MF) and Sézary syndrome (SS) over a time period of 19 years in 1998-2016 by using a nation-wide patient register containing data on all diagnosed MF and SS cases in Finland. RESULTS: The prevalence of diagnosed MF and SS rose from 2.04 to 5.38/100000, and from 0.16 to 0.36/100000 for MF and SS respectively during 1998-2016. We found a substantial decrease in inpatient treatment of MF/SS in the past two decades with a mean of 2 inpatient days/patient/year due to MF/SS in 2016, while the mean numbers of MF/SS related outpatient visits remained stable at 8 visits/year/patient. Most MF/SS-related outpatient visits occurred in the medical specialty of dermatology. In a ten-year follow-up after MF/SS diagnosis, the main causes for outpatient visits and inpatient stays were MF/SS itself, other cancers, and other skin conditions. Also cardiovascular disease and infections contributed to the number of inpatient days. Mean total hospital costs decreased from 11,600 eur/patient/year to 3600 eur/patient/year by year 4 of the follow-up, and remained at that level for the remainder of the 10-year follow-up. MF/SS accounted for approximately half of the hospital costs of these patients throughout the follow-up. CONCLUSIONS: The nearly 3-fold increase in prevalence of diagnosed MF/SS during 1998-2016 puts pressure on the health care system, as this is a high-cost patient group with a heavy burden of comorbidities. The challenge can be in part answered by shifting the treatment of MF/SS to a more outpatient-based practice, and by adapting new pharmacotherapy, as has been done in Finland.


Subject(s)
Mycosis Fungoides/epidemiology , Sezary Syndrome/epidemiology , Skin Neoplasms/epidemiology , Delivery of Health Care , Finland/epidemiology , Humans , Mycosis Fungoides/diagnosis , Mycosis Fungoides/therapy , Prevalence , Sezary Syndrome/diagnosis , Sezary Syndrome/therapy , Skin Neoplasms/diagnosis , Skin Neoplasms/therapy
3.
Acta Derm Venereol ; 101(2): adv00404, 2021 Feb 19.
Article in English | MEDLINE | ID: mdl-33491093

ABSTRACT

Previous research presents pulsed dye laser-mediated photodynamic therapy as a promising alternative to conventional red-light photodynamic therapy. In this study, 60 patients with 2 or more actinic keratoses randomly received either of these treatments on each side of the head. A physician blinded to the treatment evaluated treatment response at 6 months for each lesion, as completely, partially or not healed. Significantly lower complete clearance rates (10.3% vs 44.9%) and lesion-specific complete clearance rates were found for pulsed dye laser-mediated photodynamic therapy (47.9%) vs conventional red-light photodynamic therapy (73.4%). Significantly lower pain scores were found for pulsed dye laser-mediated photodynamic therapy, with a mean numerical rating of 2.3, compared with 4.1 for conventional red-light photodynamic therapy. The study population had a mean of 7.9 lesions, and 78% of patients had been treat-ed previously for actinic keratoses on the treatment area. To conclude, in a population with severe sun dam-age, pulsed dye laser-mediated photodynamic therapy seems less effective than conventional red-light photo-dynamic therapy. Pulsed dye laser-mediated photodynamic therapy may still be a treatment option for patients who are not compliant with conventional red-light photodynamic therapy.


Subject(s)
Keratosis, Actinic , Lasers, Dye , Photochemotherapy , Aminolevulinic Acid/adverse effects , Humans , Keratosis, Actinic/diagnosis , Keratosis, Actinic/drug therapy , Lasers, Dye/adverse effects , Photochemotherapy/adverse effects , Photosensitizing Agents/adverse effects , Treatment Outcome
5.
Orphanet J Rare Dis ; 9: 160, 2014 Nov 12.
Article in English | MEDLINE | ID: mdl-25928531

ABSTRACT

BACKGROUND: Subcutaneous panniculitis-like T cell lymphomas represent a rare and difficult to diagnose entity of cutaneous T cell lymphomas. SPTL affects predominantly young adults and presents with multifocal subcutaneous nodules and frequently associated autoimmune features. The pathogenesis of SPTL is not completely understood. METHODS: The aim of this study was to unravel molecular pathways critical to the SPTL pathogenesis. Therefore, we analyzed 23 skin samples from 20 newly diagnosed SPTL patients and relevant control samples of adipose and non-malignant panniculitis tissue by using gene expression microarray, quantitative PCR, and two-colour immunohistochemistry. RESULTS: Interestingly, indoleamine 2,3-dioxygenase (IDO-1), an immunotolerance-inducing enzyme, was among the most highly overexpressed genes in all comparisons. The expression of Th1-specific cytokines, known to be associated with autoimmune inflammation (i.e. IFNG, CXCR3, CXCL9, CXCL10, CXCL11, and CCL5), were also significantly increased. Confirmed using immunohistochemistry, the morphologically malignant lymphocytes expressed CXCR3 and CXCL9. IDO-1 expression was found both in some morphologically malignant lymphocytes rimming the adipocytes and in surrounding CD11c(-) CD68(-) cells but not in CD11c(+) dendritic cells in the microenvironment. The proportion of FoxP3+ cells in SPTL exceeded that in the benign panniculitis samples. CONCLUSIONS: Our results indicate that the up regulation of the tolerogenic IDO-1 together with the up regulation of IFNG, CXCR3 ligands, and CCL5 are features of SPTL lesions. We anticipate that the IFNG-inducible IDO-1 expression contributes to the formation of an immunosuppressive microenvironment, favorable for the malignant T cells. This study provides a relevant molecular basis for further studies exploring novel therapeutic means for subcutaneous T cell lymphoma.


Subject(s)
Autoimmunity/genetics , Immune Tolerance/genetics , Lymphoma, T-Cell/genetics , Panniculitis/genetics , Skin/metabolism , Up-Regulation/genetics , Adolescent , Adult , Aged , Chemokine CXCL9/genetics , Chemokine CXCL9/metabolism , Chemokines, CXC/genetics , Chemokines, CXC/metabolism , Cytokines/genetics , Cytokines/metabolism , Female , Humans , Immunohistochemistry , Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics , Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism , Lymphoma, T-Cell/metabolism , Male , Middle Aged , Oligonucleotide Array Sequence Analysis , Panniculitis/metabolism , Real-Time Polymerase Chain Reaction , Young Adult
6.
PLoS One ; 8(10): e76281, 2013.
Article in English | MEDLINE | ID: mdl-24098463

ABSTRACT

The pathomechanism of mycosis fungoides (MF), the most common type of primary cutaneous T-cell lymphomas (CTCLs) and a malignancy of non-recirculating, skin-resident T-cells, is unknown albeit underlying viral infections have been sought for. Human endogenous retroviruses (HERVs) are ancient retroviral sequences in the human genome and their transcription is often deregulated in cancers. We explored the transcriptional activity of HERV sequences in a total of 34 samples comprising MF and psoriasis skin lesions, as well as corresponding non-malignant skin using a retrovirus-specific microarray and quantitative RT-PCR. To identify active HERV-W loci, we cloned the HERV-W specific RT-PCR products, sequenced the cDNA clones and assigned the sequences to HERV-W loci. Finally, we used immunohistochemistry on MF patient and non-malignant inflammatory skin samples to confirm specific HERV-encoded protein expression. Firstly, a distinct, skin-specific transcription profile consisting of five constitutively active HERV groups was established. Although individual variability was common, HERV-W showed significantly increased transcription in MF lesions compared to clinically intact skin from the same patient. Predominantly transcribed HERV-W loci were found to be located in chromosomes 6q21 and 7q21.2, chromosomal regions typically altered in CTCL. Surprisingly, we also found the expression of 7q21.2/ERVWE1-encoded Syncytin-1 (Env) protein in MF biopsies and expression of Syncytin-1 was seen in malignant lymphocytes, especially in the epidermotropic ones, in 15 of 30 cases studied. Most importantly, no Syncytin-1 expression was detected in inflammatory dermatosis (Lichen ruber planus) with skin-homing, non-malignant T lymphocytes. The expression of ERVWE1 mRNA was further confirmed in 3/7 MF lesions analyzed. Our observations strengthen the association between activated HERVs and cancer. The study offers a new perspective into the pathogenesis of CTCL since we demonstrate that differences in HERV-W transcription levels between lesional MF and non-malignant skin are significant, and that ERVWE1-encoded Syncytin-1 is expressed in MF lymphoma cells.


Subject(s)
Endogenous Retroviruses/genetics , Gene Products, env/genetics , Lymphoma, T-Cell, Cutaneous/genetics , Pregnancy Proteins/genetics , Cluster Analysis , Female , Gene Expression Profiling , Gene Products, env/metabolism , Genetic Loci , Humans , Lichen Planus/genetics , Lichen Planus/metabolism , Lichen Planus/pathology , Lymphoma, T-Cell, Cutaneous/pathology , Male , Mycosis Fungoides/genetics , Pregnancy Proteins/metabolism , Psoriasis/genetics , RNA, Messenger/genetics , Skin/metabolism , Skin/pathology , Transcription, Genetic
7.
Acta Derm Venereol ; 92(3): 258-63, 2012 May.
Article in English | MEDLINE | ID: mdl-22678563

ABSTRACT

Bexarotene is an oral retinoid shown to be active against the cutaneous manifestations of cutaneous T-cell lym-phoma (CTCL). Literature on the efficacy, dosing and side-effects of bexarotene is sparse. We present here data on 37 Finnish patients with CTCL treated with bexarotene during the last 10 years. Bexarotene was equally effective as monotherapy or when combined with other treatment modalities, resulting in overall responses of approximately 75%. Early-stage CTCL responded better than advanced-stage CTCL (83% vs. 33%). The mean time to observable response was 3 months and the mean duration of the response was 21 months. The dose of bexarotene was generally lower than recommended due to side-effects. Abrupt elevation of liver transaminases, resulting in cessation of treatment, was observed in 4 (11%) patients. We conclude that the dose of bexarotene should be titrated individually to achieve optimal results. Maintenance therapy with low-dose bexarotene is a feasible alternative.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Lymphoma, T-Cell, Cutaneous/drug therapy , Lymphoma, T-Cell, Cutaneous/pathology , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Tetrahydronaphthalenes/therapeutic use , Adult , Aged , Aged, 80 and over , Alanine Transaminase/blood , Anticarcinogenic Agents/adverse effects , Aspartate Aminotransferases/blood , Bexarotene , Combined Modality Therapy , Finland , Humans , Hypercholesterolemia/chemically induced , Hypertriglyceridemia/chemically induced , Hypothyroidism/chemically induced , Liver/enzymology , Liver/physiopathology , Middle Aged , Neoplasm Staging , Neutropenia/chemically induced , Retrospective Studies , Tetrahydronaphthalenes/adverse effects
8.
J Invest Dermatol ; 128(9): 2304-9, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18337827

ABSTRACT

Subcutaneous panniculitis-like T-cell lymphomas (SPTLs) represent a rare, difficult-to-diagnose, and poorly characterized subtype of cutaneous T-cell lymphomas (CTCLs) affecting younger people more than the other CTCL forms. We performed a thorough clinical, immunohistological, and molecular analysis of nine Finnish SPTL patients. Specifically, we performed single-cell comparative genomic hybridization (CGH) from laser microdissected, morphologically malignant SPTL cells, as well as loss of heterozygosity (LOH) and fluorescence in situ hybridization (FISH) analysis for the NAV3 (neuron navigator 3) gene. CGH revealed large numbers of DNA copy number changes, the most common of which were losses of chromosomes 1pter, 2pter, 10qter, 11qter, 12qter, 16, 19, 20, and 22 and gains of chromosomes 2q and 4q. Some of the DNA copy number aberrations in SPTL, such as loss of 10q, 17p, and chromosome 19, overlap with those characteristic of common forms of CTCL (mycosis fungoides (MF) and Sezary syndrome (SS)), whereas 5q and 13q gains characterize SPTL. Allelic NAV3 aberrations (LOH or deletion by FISH), previously found in MF and SS, were identified in 44% of the SPTL samples. This study demonstrates that SPTL is also moleculocytogenetically a uniform entity of CTCL and supports the current World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification defining SPTL as a subgroup of its own.


Subject(s)
Lymphoma, T-Cell, Cutaneous/genetics , Lymphoma, T-Cell, Cutaneous/pathology , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Adolescent , Adult , Chromosome Aberrations , Chromosomes, Human, Pair 13/genetics , Chromosomes, Human, Pair 5/genetics , Female , Gene Deletion , Gene Dosage/genetics , Humans , Loss of Heterozygosity/genetics , Lymphoma, T-Cell, Cutaneous/classification , Male , Membrane Proteins/genetics , Middle Aged , Mycosis Fungoides/genetics , Nerve Tissue Proteins/genetics , Panniculitis/pathology , Retrospective Studies , Sezary Syndrome/genetics , Skin Neoplasms/classification , World Health Organization
9.
Blood ; 111(2): 838-45, 2008 Jan 15.
Article in English | MEDLINE | ID: mdl-17934071

ABSTRACT

In the WHO classification, subcutaneous panniculitis-like T-cell lymphoma (SPTL) is defined as a distinct type of T-cell lymphoma with an aggressive clinical behavior. Recent studies suggest that distinction should be made between SPTL with an alpha/beta T-cell phenotype (SPTL-AB) and SPTL with a gammadelta T-cell phenotype (SPTL-GD), but studies are limited. To better define their clinicopathologic features, immunophenotype, treatment, and survival, 63 SPTL-ABs and 20 SPTL-GDs were studied at a workshop of the EORTC Cutaneous Lymphoma Group. SPTL-ABs were generally confined to the subcutis, had a CD4-, CD8+, CD56-, betaF1+ phenotype, were uncommonly associated with a hemophagocytic syndrome (HPS; 17%), and had a favorable prognosis (5-year overall survival [OS]: 82%). SPTL-AB patients without HPS had a significantly better survival than patients with HPS (5-year OS: 91% vs 46%; P<.001). SPTL-GDs often showed (epi)dermal involvement and/or ulceration, a CD4-, CD8-, CD56+/-, betaF1- T-cell phenotype, and poor prognosis (5-year OS: 11%), irrespective of the presence of HPS or type of treatment. These results indicate that SPTL-AB and SPTL-GD are distinct entities, and justify that the term SPTL should further be used only for SPTL-AB. SPTL-ABs without associated HPS have an excellent prognosis, and multiagent chemotherapy as first choice of treatment should be questioned.


Subject(s)
Lymphoma, T-Cell, Cutaneous/classification , Lymphoma, T-Cell, Cutaneous/diagnosis , Lymphoma, T-Cell, Cutaneous/mortality , Panniculitis/classification , Panniculitis/diagnosis , Panniculitis/mortality , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , CD4 Antigens/metabolism , CD56 Antigen/metabolism , CD8 Antigens/metabolism , Carrier Proteins/metabolism , Child , Diagnosis, Differential , Disease-Free Survival , Education , Female , Humans , Lymphoma, T-Cell, Cutaneous/drug therapy , Lymphoma, T-Cell, Cutaneous/metabolism , Lymphoma, T-Cell, Cutaneous/pathology , Male , Microfilament Proteins/metabolism , Middle Aged , Panniculitis/drug therapy , Panniculitis/metabolism , Panniculitis/pathology , Phenotype , Receptors, Antigen, T-Cell, alpha-beta/metabolism , Receptors, Antigen, T-Cell, gamma-delta/metabolism , Survival Rate , T-Lymphocytes/metabolism , T-Lymphocytes/pathology
10.
Genes Chromosomes Cancer ; 47(2): 107-17, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17985357

ABSTRACT

Cutaneous T-cell lymphoma (CTCL) patients have an increased risk of certain secondary cancers, the most common of which are lung cancers, especially small cell lung cancer. To reveal the molecular pathogenesis underlying CTCL-associated lung cancer, we analyzed genomic aberrations in CTCL-associated and reference lung cancer samples. DNA derived from microdissected lung cancer cells of five CTCL-associated lung cancers and five reference lung cancers without CTCL association was analyzed by comparative genomic hybridization (CGH). Fluorescent in situ hybridization (FISH), immunohistochemistry (IHC), and loss of heterozygosity (LOH) analysis were performed for selected genes. In CTCL-associated lung cancer, CGH revealed chromosomal aberrations characterizing both lung cancer and CTCL, but also losses of 1p, and 19, and gains of 4q and 7, hallmarks of CTCL. LOH for the CTCL-associated NAV3 gene was detected in two of the four informative primary lung cancers. FISH revealed increased copy number of the KIT gene in 3/4 of CTCL-associated lung cancers and 1/5 of primary lung cancers. PDGFRA and VEGFR2 copy numbers were also increased. IHC showed moderate KIT expression when the gene copy number was increased. CTCL-associated lung cancer shows chromosomal aberrations different from primary lung cancer, especially amplifications of 4q, a chromosome arm frequently deleted in the latter tumor type. Copy numbers and expression of selected genes in chromosome 4 differed between CTCL-associated and reference lung cancers. These preliminary observations warrant further prospective studies to identify the common underlying factors between CTCL and CTCL-associated lung cancer.


Subject(s)
Carcinoma, Small Cell/genetics , Chromosome Aberrations , Lung Neoplasms/genetics , Lymphoma, T-Cell, Cutaneous/genetics , Aged , Gene Dosage , Humans , In Situ Hybridization, Fluorescence , Male , Middle Aged , Nucleic Acid Hybridization
11.
Clin Cancer Res ; 12(16): 4812-21, 2006 Aug 15.
Article in English | MEDLINE | ID: mdl-16914566

ABSTRACT

PURPOSE: Increased production of Th2 cytokines characterizes Sezary syndrome, the leukemic form of cutaneous T-cell lymphomas (CTCL). To identify the molecular background and to study whether shared by the most common CTCL subtype, mycosis fungoides, we analyzed the gene expression profiles in both subtypes. EXPERIMENTAL DESIGN: Freshly isolated cells from 30 samples, representing skin, blood, and enriched CD4(+) cell populations of mycosis fungoides and Sezary syndrome, were analyzed with Affymetrix (Santa Clara, CA) oligonucleotide microarrays, quantitative PCR, or immunohistochemistry. The gene expression profiles were combined with findings of comparative genomic hybridization of the same samples to identify chromosomal changes affecting the aberrant gene expression. RESULTS: We identified a set of Th1-specific genes [e.g., TBX21 (T-bet), NKG7, and SCYA5 (RANTES)] to be down-regulated in Sezary syndrome as well as in a proportion of mycosis fungoides samples. In both Sezary syndrome and mycosis fungoides blood samples, the S100P and LIR9 gene expression was up-regulated. In lesional skin, IL7R and CD52 were up-regulated. Integration of comparative genomic hybridization and transcriptomic data identified chromosome arms 1q, 3p, 3q, 4q, 12q, 16p, and 16q as likely targets for new CTCL-associated gene aberrations. CONCLUSIONS: Our findings revealed several new genes involved in CTCL pathogenesis and potential therapeutic targets. Down-regulation of a set of genes involved in Th1 polarization, including the major Th1-polarizing factor, TBX21, was for the first time associated with CTCL. In addition, a plausible explanation for the proliferative response of CTCL cells to locally produced interleukin-7 was revealed.


Subject(s)
Mycosis Fungoides/genetics , Mycosis Fungoides/immunology , Sezary Syndrome/genetics , Sezary Syndrome/immunology , Skin Neoplasms/genetics , Skin Neoplasms/immunology , Th1 Cells/physiology , Cytotoxicity, Immunologic/genetics , Cytotoxicity, Immunologic/immunology , Down-Regulation , Gene Dosage , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry/methods , Oligonucleotide Array Sequence Analysis , Polymerase Chain Reaction/methods , Th1 Cells/immunology
12.
Cancer Res ; 65(18): 8101-10, 2005 Sep 15.
Article in English | MEDLINE | ID: mdl-16166283

ABSTRACT

Multicolor fluorescent in situ hybridization (FISH) was used to identify acquired chromosomal aberrations in 12 patients with mycosis fungoides or Sézary syndrome, the most common forms of primary cutaneous T-cell lymphoma (CTCL). The most frequently affected chromosome was 12, which showed clonal deletions or translocations with a break point in 12q21 or 12q22 in five of seven consecutive Sézary syndrome patients and a clonal monosomy in the sixth patient. The break point of a balanced translocation t(12;18)(q21;q21.2), mapped in the minimal common region of two deletions, fine mapped to 12q2. By locus-specific FISH, the translocation disrupted one gene, NAV3 (POMFIL1), a human homologue of unc-53 in Caenorhabditis elegans. A missense mutation in the remaining NAV3 allele was found in one of six cases with a deletion or translocation. With locus-specific FISH, NAV3 deletions were found in the skin lesions of four of eight (50%) patients with early mycosis fungoides (stages IA-IIA) and in the skin or lymph node of 11 of 13 (85%) patients with advanced mycosis fungoides or Sézary syndrome. Preliminary functional studies with lentiviral small interfering RNA-based NAV3 silencing in Jurkat cells and in primary lymphocytes showed enhanced interleukin 2 expression (but not CD25 expression). Thus, NAV3 may contribute to the growth, differentiation, and apoptosis of CTCL cells as well as to the skewing from Th1-type to Th2-type phenotype during disease progression. NAV3, a novel putative haploinsufficient tumor suppressor gene, is disrupted in most cases of the commonest types of CTCL and may thus provide a new diagnostic tool.


Subject(s)
Chromosome Aberrations , Gene Deletion , Lymphoma, T-Cell, Cutaneous/genetics , Membrane Proteins/genetics , Nerve Tissue Proteins/genetics , Skin Neoplasms/genetics , Alleles , Chromosome Breakage , Chromosome Mapping , Chromosomes, Human, Pair 12/genetics , Gene Silencing , Humans , In Situ Hybridization, Fluorescence , Interleukin-2/biosynthesis , Interphase/genetics , Lymphoma, T-Cell, Cutaneous/metabolism , Membrane Proteins/biosynthesis , Nerve Tissue Proteins/biosynthesis , Sezary Syndrome/genetics , Translocation, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...